User login
Key clinical point: Higher baseline serum levels of choline, betaine, and phenylacetylglutamine are associated with increased risk for incident lethal prostate cancer.
Major finding: Compared with the patients in the first quartile, the risk for incident lethal prostate cancer was higher in those with higher baseline levels of choline (odds ratio [OR] for third and fourth quartile, 2.37 and 2.19, respectively; P for trend = .005), betaine (OR for third and fourth quartile, 2.13 and 1.86, respectively; P for trend = .11), and phenylacetylglutamine (OR for third and fourth quartile, 2.54 and 2.55, respectively; P for trend = .003).
Study details: A study of 173 patients with lethal prostate cancer and 519 healthy individuals from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial.
Disclosures: This study was supported by grants from National Cancer Institute and Prostate Cancer Foundation. The authors held patents and/or received consulting fees/research grants/royalties from various sources.
Source: Reichard CA et al. Cancer Epidemiol Biomarkers Prev. 2021 Oct 28. doi: 10.1158/1055-9965.
Key clinical point: Higher baseline serum levels of choline, betaine, and phenylacetylglutamine are associated with increased risk for incident lethal prostate cancer.
Major finding: Compared with the patients in the first quartile, the risk for incident lethal prostate cancer was higher in those with higher baseline levels of choline (odds ratio [OR] for third and fourth quartile, 2.37 and 2.19, respectively; P for trend = .005), betaine (OR for third and fourth quartile, 2.13 and 1.86, respectively; P for trend = .11), and phenylacetylglutamine (OR for third and fourth quartile, 2.54 and 2.55, respectively; P for trend = .003).
Study details: A study of 173 patients with lethal prostate cancer and 519 healthy individuals from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial.
Disclosures: This study was supported by grants from National Cancer Institute and Prostate Cancer Foundation. The authors held patents and/or received consulting fees/research grants/royalties from various sources.
Source: Reichard CA et al. Cancer Epidemiol Biomarkers Prev. 2021 Oct 28. doi: 10.1158/1055-9965.
Key clinical point: Higher baseline serum levels of choline, betaine, and phenylacetylglutamine are associated with increased risk for incident lethal prostate cancer.
Major finding: Compared with the patients in the first quartile, the risk for incident lethal prostate cancer was higher in those with higher baseline levels of choline (odds ratio [OR] for third and fourth quartile, 2.37 and 2.19, respectively; P for trend = .005), betaine (OR for third and fourth quartile, 2.13 and 1.86, respectively; P for trend = .11), and phenylacetylglutamine (OR for third and fourth quartile, 2.54 and 2.55, respectively; P for trend = .003).
Study details: A study of 173 patients with lethal prostate cancer and 519 healthy individuals from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial.
Disclosures: This study was supported by grants from National Cancer Institute and Prostate Cancer Foundation. The authors held patents and/or received consulting fees/research grants/royalties from various sources.
Source: Reichard CA et al. Cancer Epidemiol Biomarkers Prev. 2021 Oct 28. doi: 10.1158/1055-9965.